To date, BeiGene has announced positive readouts from 10 Phase 3 pivotal studies across multiple tumor types and disease settings such as NSCLC, Small Cell Lung Cancer, Gastric Cancer, ESCC ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

ESCC accounts for 80% of cases of esophageal ... including a study involving patients with extensive stage small cell lung cancer. However, phase 1a/1b results published in JAMA Oncology in ...

squamous non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma, bladder ...

Shortly after the FDA delayed a decision for Novartis and BeiGene’s tislelizumab in previously treated esophageal squamous cell carcinoma (ESCC), the ... non-small cell lung cancer (NSCLC).

Yaoyao Zhu, MD, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Shanghai, China, presented the new research at the IASLC World Conference on Lung Cancer (WCLC) 2024 on September 10.

The drug is already approved in the EU to treat certain cases of oesophageal squamous cell carcinoma (ESCC), gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and non-small lung cancer. The ...

New findings in indicate that periostin, or POSTN, promotes ESCC progression by enhancing cancer and stromal cell migration in cancer-associated fibroblasts (CAFs). Therefore, it may be a novel ...